Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy.

Yardley, Denise A

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. [electronic resource] - Breast cancer research and treatment Apr 2020 - 647-655 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article

1573-7217

10.1007/s10549-020-05563-z doi


Adult
Aged
Anthracyclines--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--metabolism
Breast Neoplasms--drug therapy
Bridged-Ring Compounds--administration & dosage
Chemotherapy, Adjuvant--mortality
Cohort Studies
Drug Resistance, Neoplasm--drug effects
Female
Follow-Up Studies
Furans--administration & dosage
Humans
Ketones--administration & dosage
Middle Aged
Neoadjuvant Therapy--mortality
Non-Randomized Controlled Trials as Topic
Prognosis
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Survival Rate
Taxoids--administration & dosage
Trastuzumab--administration & dosage